drug_type
RELEVANT_DRUG
intervention_type
Biological (gene-modified cellular therapy)
drug_description
Autologous patient T cells genetically engineered to express a chimeric antigen receptor targeting CD7, administered as a single IV infusion after lymphodepletion to recognize and kill CD7-expressing malignant T cells in relapsed/refractory T-ALL/LBL.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are genetically engineered to express a chimeric antigen receptor that binds CD7. Upon engagement of CD7 on malignant T cells, CAR signaling (CD3ζ with co-stimulation) activates the T cells, driving proliferation, cytokine release, and perforin/granzyme‑mediated cytotoxic killing, leading to clearance of CD7‑expressing T‑lineage blasts in R/R T‑ALL/LBL.
drug_name
Autologous anti-CD7 CAR T-cell therapy
nct_id_drug_ref
NCT05909527